Cholesterol Lowering Drug Market, By Drug Class (Statins & Combination, PCSK9 Inhibitors, Bile Acid Sequestrants, Fibrates, Cholesterol Absorption Inhibitors and Others), By Indication (Hypercholesterolemia, Coronary Artery Disease, Higher Triglycerides), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Trends, Analysis, and Forecast till 2030

Cholesterol Lowering Drug Market accounted for US$ 8.8 billion in 2020 and is estimated to be US$ 18.7 billion by 2029 and is anticipated to register a CAGR of 7.5%.

Cholesterol lowering drugs are used to control or lower down cholesterol and one of the most preferred medication is Statins, also known as HMG-CoA reductase inhibitors, are a class of lipid-lowering medications that reduce illness and mortality in those who are at high risk of cardiovascular disease. They are the most common cholesterol-lowering drugs. Low-density lipoprotein (LDL) carriers of cholesterol play a key role in the development of atherosclerosis and coronary heart disease via the mechanisms described by the lipid hypothesis. Statins are effective in lowering LDL cholesterol and so are widely used for primary prevention in people at high risk of cardiovascular disease, as well as in secondary prevention for those who have developed cardiovascular disease. Side effects of statins include muscle pain, increased risk of Diabetes mellitus, and abnormal blood levels of liver enzymes. Additionally, they have rare but severe adverse effects, particularly muscle damage. They inhibit the enzyme HMG-CoA reductase which plays a central role in the production of cholesterol. High cholesterol levels have been associated with cardiovascular disease. There are various forms of statins, some of which include atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin. Bile acid sequestrants can be difficult to use as they decrease the absorption of multiple drugs, may increase triglyceride levels, and cause constipation and other GI side effects. PCSK9 inhibitors are very useful when maximally tolerated statin therapy does not reduce LDL sufficiently and in statin intolerant patients. PCSK9 inhibitors have very few side effects.

Increase in prevalence of Coronary Artery Disease

Increase in prevalence of coronary artery disease is the major driver for the cholesterol lowering drugs market. For Instance, Cardiovascular diseases (CVDs) are the leading cause of death globally. An estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths. Of these deaths, 85% were due to heart attack and stroke.

Side Effects

Adverse effects associated with statin therapy were the development of diabetes and muscle disorders. After many years of statin use it was recognized that statins increase the risk of developing diabetes. For Instance, High-dose simvastatin was associated with a 44 percent increased risk of developing diabetes, while for low-dose simvastatin the increased risk was 28 percent. High-dose atorvastatin was linked to a 37 percent increased diabetes risk, the study found. Adverse side effect might hamper the market of cholesterol lowering drugs.

Cholesterol Lowering Drug Market is segmented based on Drug Class, Indication, Distribution Channel and region.

On the basis of Drug Class, the Global Cholesterol Lowering Drug Market is segmented into Statin & Combination, PCSK9 Inhibitors, Bile Acid Sequestrants, Fibrates, Cholesterol Absorption Inhibitors and Others. Based on Indication, the target market is segmented into Hypercholesterolemia, Coronary Artery Disease, and Higher Triglycerides. On the basis of Distribution Channel, the target market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies.

Regional Insights:

On region the Cholesterol Lowering Drug Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to lead the market during forecast year due to growing awareness about bad cholesterol and development of drugs. For Instance, in May 2019, Esperion - a U.S. pharmaceutical company, announced the FDA approval for new drug applications (NDAs) involving the bempedoic acid.                                

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2019 to 2029. For the purpose of this study, has segmented the Global Cholesterol Lowering Drug Market report based on Drug Class, Indication, Distribution Class and region.

Cholesterol Lowering Drug Market, By Region:

• North America
  • Middle East & Africa
    • • GCC
      • Israel
      • South Africa
      • Rest of Middle East & Africa
  • Latin America
    • • Brazil
      • Mexico
      • Rest of Latin America
  • Asia Pacific
    • • China
      • India
      • Japan
      • South Korea
      • Rest of Asia Pacific
  • Europe
    • • Germany
      • UK
      • France
      • Russia
      • Italy
      • Rest of Europe
  • • U.S.
    • Canada

The key players operating in the Cholesterol Lowering Drug Market includes Sanofi, Pfizer, Inc., GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Amgen Inc., Takeda Pharmaceutical Company Limited, Sun Pharmaceutical Industries Ltd. and AbbVie, Inc. For Instance, On 6^th Jan 2020, Novartis successfully completes acquisition of The Medicines Company, adding a potentially first-in-class, investigational cholesterol-lowering therapy inclisiran.

• Sanofi*
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Pfizer, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• GlaxoSmithKline plc
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Novartis AG
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Merck & Co., Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Amgen Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• AbbVie, Inc.
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies